231
Participants
Start Date
September 6, 2012
Primary Completion Date
July 31, 2015
Study Completion Date
January 18, 2021
Octreotide LAR
"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
177Lu-DOTA0-Tyr3-Octreotate
Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Digestive Oncology, Leuven Cancer Institute, Leuven
Charité, Virchow-Klinikum, Gastroentrology, Hepatology & Endocrinology, Berlin
Hôpital la Timone /CHU Marseille, Marseille
Perelman Center for Advanced Medicine, Philadelphia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
IEO Istituto Europeo di Oncologia, Milan
Duke University Medical Center, Durham
Ramon y Cajal University Hospital, Madrid
Institut Claudius Regaud, Toulouse
Moffitt Cancer Center, Tampa
Henry-Joyce Cancer Clinic, Nashville
Hotel Dieu/CHU Nantes, Nantes
Kettering Medical Center, Kettering
Istituto Oncologico Romagnolo per lo Studio dei Tumori, Meldola
University of Iowa Hospitals and Clinics, Iowa City
Universitätsmedizin Mainz, Medizinische Klinik I Schwerpunkt Endokrinologie, Mainz
Mayo Clinic, Rochester
Azienda Ospedaliero - Universitaria Pisana (Presidio Ospedaliero S. Chiara), Pisa
Presidio Osp. Di Macerata, Macerata
Centre Hospitalier Lyon-Sud, Lyon
University of Texas MD Anderson Cancer Center, Houston
Excel Diagnostics and Nuclear Oncology Center, Houston
Klinikum Rechts Isar, Nuclear Medicine, Munich
Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles
Hôpital Beaujon AP-HP, Clichy
Stanford Cancer Center, Palo Alto
Institut Gustave Roussy, Villejuif
Zentralklinik Bad Berka, Bad Berka
Northwestern Medical Faculty Foundation, Chicago
Dana Farber Cancer Institute, Boston
"Università Sapienza di Roma, Facoltà di Medicina e Psicologia, Ospedale S. Andrea-Roma", Roma
Centro Hospitalar e Universitario de Coimbra, Coimbra
Instituto Português de Oncologia, Porto
University Hospital of Bellvitge, Hospitalet de Llobregat (Barcelona)
University of Oxford, Oxford
Beatson Oncology Centre, Glasgow
Royal Free Hospital, London
Imperial College Healthcare Trust, Hammersmith Hospital, London
The Christie NHS foundation Trust, Manchester
Lead Sponsor
Advanced Accelerator Applications
INDUSTRY